Roche Diagnostics launches cobas e 411 immunoassay analyzer

Indianapolis, USA. Roche Diagnostics has released its next generation bench-top immunoassay analyzer, the cobas e 411 aimed at the low- to mid- volume immunoassay market.

"Roche Diagnostics is committed to being the leader in the immunoassay market. The cobas e 411 analyzer is evidence of our strength in innovation to provide greater efficiency and increased productivity in the laboratory," said Andy Thomson, Senior Vice President and General Manager, Roche Centralized Diagnostics.

The cobas e 411 analyzer can operate independently, as a dedicated STAT analyzer, or as part of a networked clinical laboratory environment. It provides results for critical assays — Troponin T, CK-MB, Myoglobin, and HCG — in as little as nine minutes. It uses electrochemiluminescence (ECL) to deliver low-end sensitivity and a broad dynamic range. It virtually eliminates unnecessary repeats and reruns, providing accurate results the first time.

The cobas platform has a standardized graphical user-interface, common assay applications and technologies, and uniform reagent carriers across analytical systems.

To top